Kodu・Aktsiate loetelu・Organon & Co

Organon & Co

Suletud

SektorTervishoid

13.73 0.07

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

13.7

Max

13.73

Põhinäitajad
By Trading Economics
Sissetulek	-292M -146M
Müük	98M 1.6B
P/E Sektori keskmine	17.539 55.725
Aktsiakasum	0.8
Dividenditootlus	0.58
Kasumimarginaal	-9.355
Töötajad	10,000
EBITDA	-38M 371M

Dividendid
By Acuity
Dividenditootlus Sektori keskmine	0.58% 2.25%
Järgmine tulemuste avaldamine	9. nov 2026
Järgmine dividendimakse kuupäev	10. dets 2026
Järgmine aktsia dividendi kuupäev (ex-date)	19. nov 2026

Turustatistika
By TradingEconomics
Turukapital	42M 3.6B
Eelmine avamishind	13.66
Eelmine sulgemishind	13.73

Uudiste sentiment

By Acuity

34%

66%

63 / 339 Pingereas Healthcare

Organon & Co Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. sept 2026, 19:25 UTC

Organon & Co is trading slightly higher, maintaining a routine pattern as it approaches the upper end of its one-month price range.

22. sept 2026, 22:01 UTC

Organon & Co is seeing a decline in after-market trading, now near the lower end of its one-month trading range since Tuesday's close.

18. sept 2026, 19:16 UTC

Organon & Co is trading roughly flat, showing little change since Thursday's close and remaining near the lower end of its one-month range.

17. sept 2026, 23:51 UTC

Organon & Co. is experiencing a modest decline in after-market trading, remaining below its 20-day moving average and near the lower end of its one-month trading range.

15. sept 2026, 19:56 UTC

Event

Organon & Co expects PDUFA action in Q2 2027, shares trading higher since Monday's close. The stock remains near the lower end of its one-month range.

2. sept 2026, 20:08 UTC

Organon & Co. shares are trading roughly flat, showing little change since Tuesday's close, amid stability near the upper end of their one-month range.

1. sept 2026, 23:01 UTC

Organon & Co. shares are lower in after-market trading, continuing a downward trend amid broader market unease over economic data indicating a growth slowdown.

28. aug 2026, 19:26 UTC

Organon & Co. shares are trading roughly flat, with no specific news identified. The stock remains near the upper end of its one-month trading range.

27. aug 2026, 23:01 UTC

Shares of Organon & Co. traded lower in after-market hours, continuing a decline observed earlier in the session without any specific company news identified.

25. aug 2026, 19:36 UTC

Organon & Co. shares are near unchanged, trading within a narrow range with no specific news identified during Tuesday's session.

24. aug 2026, 23:02 UTC

Organon & Co shares are trading lower in after-market hours. Broader geopolitical tensions, particularly the U.S.-Iran situation, may be influencing market sentiment.

21. aug 2026, 23:41 UTC

Organon & Co. shares are lower in after-hours trading, following a decline from earlier highs and reaching a session low. No specific news was identified.

20. aug 2026, 22:01 UTC

Organon & Co shares are trading lower in after-market hours, continuing a downward trend since Thursday's close without any specific news to explain the movement.

19. aug 2026, 23:01 UTC

Organon & Co shares declined in after-hours trading, reflecting unusual weakness since Wednesday's close. The stock is near the lower end of its one-month range.

18. aug 2026, 23:51 UTC

Organon & Co shares are higher in after-market trading, reaching a maximum cumulative return shortly after Tuesday's close. No specific news was identified.

14. aug 2026, 19:26 UTC

Organon & Co. shares are trading roughly flat, remaining above their 20-day moving average and near the upper end of their one-month range.

13. aug 2026, 23:11 UTC

Organon & Co. shares are trading lower in after-market hours, despite an initial uptick, and remain near the upper end of their one-month trading range.

7. aug 2026, 20:06 UTC

Shares of Organon & Co. are higher today, continuing a trend since Thursday's close amid a broader market increase. No specific company news was identified.

6. aug 2026, 23:11 UTC

Shares of Organon & Co. are trading lower in after-market hours, reflecting routine action within its one-month trading range. No specific news was identified.

Võrdlus sarnastega

Hinnamuutus

Organon & Co Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Organon & Co aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

63 / 339 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.